Polyphor offers PEMdrug candidates, which are derived from its proprietary Protein Epitope Mimetic (PEM) Technology platform. The offered products include the following compounds:

• POL6326 (CXCR4 antagonist, several indications, Phase II)
• POL7080 (antibiotic, Phase I)
• POL6014 (elastase inhibitor, pre-clincial)

 

• Licensing opportunities
  • POL6326
  • POL7080
  • POL6014
• Collaboration opportunities
  • PEM antibiotics
  • Chemokine receptor CCR10
  • Chemokine receptor CXCR7
  • Formyl peptide receptors
  • Ion channels
  • Protease platform
  • MacroFinder^® collaboration
  • PEMfinder^® collaborations
• Track record & alliances
  • Allergan Inc.
  • Axxam S.p.A.
  • Acino Holding Ltd
  • Novartis Pharma AG

Polyphor Ltd
Hegenheimermattweg 125
CH-4123 Allschwil
Switzerland
Tel. +41 61 567 16 00
Fax +41 61 567 16 01
info@polyphor.com

Last modified:   20.02.2012